(CLNN) – StreetInsider.com Reports
-
Clene (CLNN) Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs
-
Clene (CLNN) Reports Reduction in Biomarker Plasma NfL Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
-
Clene (CLNN) Provides Update on ALS Clinical Development Meeting With FDA
-
Clene (CLNN) Reports Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
-
Clene Inc. (CLNN) Tops Q3 EPS by 7c
-
Clene (CLNN)Announces National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS
-
Clene (CLNN) Announces 3M Share Offering by Selling Stockholders
-
Clene, Inc. (CLNN) PT Lowered to $5 at Benchmark
-
Clene, Inc. (CLNN) PT Lowered to $5 at Canaccord Genuity
-
Clene, Inc. (CLNN) PT Lowered to $7 at H.C. Wainwright
-
Clene (CLNN) Prices 50M Share Offering at $0.80/sh
-
Clene (CLNN) Announces Launch of Proposed Public Offering
-
Clene's (CLNN) CNM-Au8 Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
-
Clene Inc. (CLNN) Misses Q1 EPS by 1c
-
Clene, Inc. (CLNN) PT Lowered to $7 at Benchmark
-
Roth/MKM Reiterates $10 PT on Clene, Inc. (CLNN)
-
Clene (CLNN) Announces CNM-Au8 Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
-
Clene (CLNN) to Announce New CNM-Au8 Data From the Healey ALS Platform Trial
-
EF Hutton Starts Clene, Inc. (CLNN) at Buy
-
Clene (CLNN) Announces New Data Show CNM-Au8 Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
-
Roth/MKM Reiterates $10 PT on Clene, Inc. (CLNN), Issues Positive Comments on Data
-
Clene (CLNN) Announces Updated VISIONARY-MS Phase 2 Trial Data
-
Clene (CLNN) Reports New Data from the VISIONARY-MS Phase 2 Study
-
Roth Capital Resumes Clene, Inc. (CLNN) at Buy, PT $10
-
Clene (CLNN) Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene, Inc. (CLNN) PT Lowered to $11 at Roth Capital
-
Clene, Inc. (CLNN) PT Lowered to $15 at H.C. Wainwright
-
Clene (CLNN) Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
-
Clene, Inc. (CLNN) PT Lowered to $4 at Maxim Group
-
Oppenheimer Downgrades Clene, Inc. (CLNN) to Perform
-
Clene, Inc. (CLNN) PT Lowered to $6 at Canaccord Genuity
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.66%
-
Clene (CLNN) to Resume Trading at 8:30 a.m.
-
Clene (CLNN) Reports Mixed Results for CNM-Au8 in Healey ALS Platform Trial
-
Clene (CLNN) Halted, News Pending
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Clene (CLNN) Presents Updated Long-Term Survival Data from RESCUE-ALS
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
-
Implied Volatility Movement
Back to CLNN Stock Lookup